China News Service, July 27th (Reporter Chen Jing) Triple-negative breast cancer is called the "most toxic and dangerous" breast cancer. Many patients have undergone multiple rounds of treatment and are still progressing. "Saveable" desperate situation.
The reporter learned on the 27th that the team of Professor Shao Zhimin, director of breast surgery at Fudan University Cancer Hospital, has prescribed a "precision treatment plan" for these "most difficult to treat" triple-negative breast cancer patients, reigniting the "light of life" for them. It is reported that after precise treatment by Chinese experts, the proportion of patients with tumor shrinkage increased from less than 10% to 29%; among them, the remission rate of some subtype triple-negative breast cancer patients reached 100%. On the afternoon of the 27th, the top international academic journal "Cell Research" (Cell Research) published the research results.
In clinical practice, doctors can quickly obtain typing results by testing four "labels". Photo courtesy of Cancer Hospital
According to reports, triple-negative breast cancer lacks targets and has a high risk of recurrence and metastasis. Patients with triple-negative breast cancer whose disease is still progressing after multiple rounds of treatment have less than 10% of their tumors shrinking after conventional treatment. Professor Shao Zhimin and Professor Wang Zhonghua’s team carried out an "umbrella" study called "FUTURE" to perform typing and genetic testing for advanced refractory triple-negative breast cancer to guide subsequent corresponding precision treatments.
Professor Shao Zhimin told reporters that his team had previously drawn a gene map of triple-negative breast cancer, and confirmed that triple-negative breast cancer is not a single type of disease, but a “mixed” group. Through the analysis of huge genetic data, the research team divided triple-negative breast cancer into 4 different subtypes, and the characteristics of cancer cells of different triple-negative breast cancer subtypes are also quite different.
The research team classified these patients in combination with classification "tags", and detected more than 500 hot genes, accurately pinpointed the characteristics of cancer cells in patients with different classifications, and provided corresponding targeted therapy.
"We are pleased to find that about 29% of these patients have significantly reduced tumors, far exceeding the 10% remission rate of current international cutting-edge treatment methods." Professor Shao Zhimin said that some patients with subtype triple-negative breast cancer have undergone immunotherapy and combination In chemotherapy, 52.6% of the tumors have shrunk; the tumor shrinkage of triple-negative breast cancer patients classified as "cavity androgen receptor type" is as high as 100%.
The expert said: "After a series of calculations and analyses, we have set up 4 commonly used clinically immunohistochemical markers as the'label' for triple-negative breast cancer subtypes. In clinical practice, doctors only need to pass these The typing results can be quickly obtained by testing 4'tags'. "Related patients only need to perform immunohistochemical testing to find the "tags", and the diagnosis has wide spreadability.
It is understood that in the FUTURE study, the research team continues to make new discoveries. Professor Shao Zhimin told reporters that the "cavity-faced androgen receptor type" triple-negative breast cancer is more malignant than expected, progresses faster, and is not sensitive to related treatments. These patients still need to further analyze their characteristics and adjust the treatment plan to obtain long-term curative effects.
These results will provide ideas for more triple-negative breast cancer research in the future. Professor Shao Zhimin said, "These new results will also promote the research and development of precision medicines." (End)